Participated · Series A · Dec 2024

NeuroKaire develops a clinical test that uses a simple blood draw and patient‑derived neurons to provide a neuronal readout of antidepressant effects, combined with clinical data and a pharmacogenetic screen covering 132 drugs. The test is designed to help clinicians identify the optimal antidepressant for individual patients, reduce trial‑and‑error prescribing, and enable faster, lower‑dose, and safer treatment. NeuroKaire also positions its technology for pharmaceutical and biotechnology partners to bring precision medicine into drug development across psychiatry and neurology. The company said it will use new funding to scale operations, expand its team, deepen research and development, and expand pharmaceutical partnerships focused on multiple psychiatric and neurological diseases. The announcement highlights ongoing efforts to expand pharmaceutical collaborations and to deploy the test in clinical and drug‑development settings. The company is based in Kearny, N.J. Genetika+ builds personalized medicine solutions for psychiatric and neurological diseases using its Brain-in-a-Dish technology. The company’s first indication, NeuroKaire, rapidly tests more than 70 approved antidepressants and combinations against an individual patient’s neurological biomarkers. Genetika+ combines these functional readouts with patients’ genetic and medical history to predict optimal drug or combination therapies, aiming to reduce trial-and-error prescribing, side effects, and time to effective treatment. The platform is positioned to enable faster treatment, lower dosing, and fewer adverse outcomes versus current practice. Several clinical studies are underway and additional trials are planned to further validate the tool. Genetika+ was founded in 2018 by Talia Cohen-Solal and Daphna Laifenfeld and is based in Tel Aviv, Israel.

Led · Seed · Oct 2024

Lidwave develops 4D LiDAR-on-chip sensors built around its proprietary Finite Coherent Ranging (FCR™) technology, integrating lasers, amplifiers, receivers and optical routing onto a single chip. The company’s coherent sensing method provides pixel-level Doppler (velocity) data alongside depth information. Lidwave plans to further develop its optical chip and launch what it calls the industry’s first software-definable 4D LiDAR sensor. The technology is positioned to reduce the cost, complexity, and reliability issues associated with legacy LiDAR systems. Lidwave is collaborating with OEMs, Tier‑1 suppliers, and major players in industrial automation and smart infrastructure to drive adoption. The company says it will seek additional partnerships to scale production and extend its technology across industries to improve safety and automation.

Participated · Series A · Feb 2023

MDI Health offers an autonomous, hyper-personalized AI medication management platform that analyzes thousands of factors to identify medication-related risks and provides recommendations in minutes instead of hours. The platform equips clinicians, payers and pharmacies to perform comprehensive medication reviews, reduce adverse drug events and improve outcomes. MDI positions its solution as an alternative to alert-based medication management tools that require laborious processes. The company cites medication-related harms as a major driver of costs and mortality and targets cost savings and improved health outcomes at scale. MDI plans to use new funding to meet rising customer demand and to scale its U.S. and Israeli R&D teams to drive product development. The company was founded in 2019 and is based in Los Angeles; its disclosures state U.S. medication-related costs total $528 billion annually.

Participated · Equity · Jun 2021

Wisio provides a marketplace where creators register and offer paid two-minute personalized videos or short written replies to followers for a fee set by the creator. The platform launched in 2020 and already hosts thousands of creators offering advice across categories like singing, mentoring, art criticism, and dating. Operating metrics cited in the article include an average willing-to-pay price of $32, roughly $40 spent by young users (age 19–44), 50% of users returning more than twice, 2,700 creators waiting to join, and a 20% commission taken by Wisio. The founders report the product generated "significant" revenue to date but did not disclose exact figures; they claim this traction was achieved without marketing spend. Wisio frames its product as building a new "Exclusive Attention" category and expects future users to expand beyond creators to include CEOs, politicians, actors, and business leaders. The company plans to automate onboarding and scale user acquisition as next steps.

Participated · Seed · Mar 2020

Convizit is a Tel Aviv and Jerusalem, Israel-based startup applying AI technologies to the product analytics market. Its platform captures every user action on every page, automatically naming and enriching events with structured context so teams do not need to pre-select, code, name or tag events. The company’s first offering is a DaaS solution that delivers pre-tagged, context-rich behavioral data and is already in use by a number of large e-retailers. That data is ready for immediate use in analytics, BI, A/B testing, marketing automation and personalization, and supports funnel analysis, friction-point identification, correlation/anomaly detection, user-journey visualization and insight generation. Led by CEO Daniel Bashari, Convizit plans to use the new funding to double its team, accelerate product R&D, and launch sales and marketing activities. Financially, the company closed a $5M seed funding round led by Pitango Venture Capital with participation from earlier investor Jumpspeed Ventures.